GEN Exclusives

More »

GEN News Highlights

More »
Nov 22, 2013

SCT, AB Biosciences Partner on Antibody Drug Development

  • Single Cell Technology (SCT) and AB Biosciences have entered a collaboration to identify therapeutic antibodies.

    SCT will utilize its patented platform to massively screen plasma cells, measure the kinetics of secreted antibodies, and sequence the cognate light and heavy chain mRNA powered by next generation sequencing. AB will select antibody targets, engineer protein antigens, and develop analytical tools to further characterize the large panel of antibodies identified by SCT's platform.

    "SCT has developed an innovative antibody discovery platform. Together with AB Biosciences' premier protein engineering capacity and astute insights in antibody drug development, we will utilize our platform to outperform traditional antibody discovery techniques," said Chun-Nan Chen, M.D., founder and CEO of SCT.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »